By supporting sustainable weight loss and reducing risks associated with obesity-related conditions, this medication can help prevent the need for more costly medical treatments in the future
WangKWuQLiZRegerMKXiongYZhongGet al
In animal studies, AOD-9604 reduced body weight gain by over 50% in obese mice during a 19-day treatment period, and significantly increased fat oxidation all without affecting insulin sensitivity or glucose regulation.[1,3] A randomized controlled trial in humans found that participants taking 1 mg of AOD-9604 daily lost an average of 2.8 kg (~6 lbs) over 23 weeks, compared to 0.8 kg (~1.7 lbs) in the placebo group
Elesclomol induces copper-dependent ferroptosis in colorectal cancer cells via degradation of ATP7A
The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for WEGOVY and any potential adverse effects on the breastfed infant from WEGOVY or from the underlying maternal condition
The consultation process involves thorough health evaluations, ensuring medication recommendations align with your health profile, insurance coverage, and preferences
